Endometrial Injury and IVF Outcome Parameters in Patients With Failed IVF Cycles
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01798862 |
Recruitment Status :
Completed
First Posted : February 26, 2013
Last Update Posted : June 10, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Repeated Implantation Failures | Procedure: Endometrial injury by hysteroscopy or pipelle sampling Procedure: Proceed to COH directly | Phase 2 Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 100 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | The Effect of Endometrial Injury on IVF Outcome Parameters in Patients With Repeated Implantation Failures |
Study Start Date : | March 2013 |
Actual Primary Completion Date : | May 2016 |
Actual Study Completion Date : | June 2016 |
Arm | Intervention/treatment |
---|---|
Experimental: Endometrial injury by hysteroscopy or pipelle sapling
Endometrial Sampling by pipelle or hysteroscopy performed once between 6th to 10th day in the cycle prior to the fresh IVF/ ICSI cycle.
|
Procedure: Endometrial injury by hysteroscopy or pipelle sampling |
Active Comparator: COH for IVF without hysteroscopy or pipelle sampling
Procedure: COH for IVF Both GnRH agonists (long, starting at day 2 or 21) with triptorelin acetate 0.1 mg (Gonapeptyl daily) and antagonists with ganirelix 0.25mg (Orgalutran) or cetrorelix 0.25mg (Cetrotide) protocols will be used; for ovarian stimulation both recombinant FSH ( Puregon) and human menopausal gonadotrophin ( Menopur) will be used. Ovarian response will be monitored by ultrasonography, oocyte retrieval will be performed 36-38 hours after the Hcg triggering and for luteal phase support 600 mg progesterone tablets ( Utrogestan) will be applied.
|
Procedure: Proceed to COH directly |
- positive bHCG rate [ Time Frame: through study completion, an average of 2 years ]
- clinical pregnancy rate [ Time Frame: 2 years ]
- live birth rate [ Time Frame: 2 years ]
- Ectopic pregnancy rate [ Time Frame: 2 years ]
- Miscarriage rate [ Time Frame: 2 years ]
- Ongoing pregnancy rate [ Time Frame: 2 years ]
- Pregnancy complications (preterm birth, placental abnormalities, bleeding throughout pregnancy, pregnancy related hypertensive disorders, IUGR and SGA) [ Time Frame: 2 years ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 25 Years to 42 Years (Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Personal history of 2 or more failed IVF/ICSI cycles (RIF)
- Age</= 42 years
- Good response with good quality embryos in previous attempts (>2)
Exclusion Criteria:
- Personal history of endometrial tuberculosis/ antituberculous treatment
- Sonographically detected hydrosalpinges
- Intramural fibroids distorting the endometrial cavity, submucous myomas or Asherman's syndrome
- Thrombophilia

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01798862
Greece | |
Assisted Reproduction Unit 3rd Department of Obstetrics & Gynecology, Attikon University Hospital | |
Athens, Attica, Greece, 12642 | |
Assisted Reproduction Unit | |
Alexandroupolis, Thrace, Greece |
Principal Investigator: | Maria Kreatsa, MD/PhD | National and Kapodistrian University of Athens | |
Principal Investigator: | Charalampos Siristatidis, MD, PhD | National Kapodistrian University of Athens |
Other Publications:
Responsible Party: | Siristatidis Charalampos, MD, PhD, Assistant Professor in Obstetrics and Gynecology / Assisted Reproduction, National and Kapodistrian University of Athens |
ClinicalTrials.gov Identifier: | NCT01798862 |
Other Study ID Numbers: |
121212 |
First Posted: | February 26, 2013 Key Record Dates |
Last Update Posted: | June 10, 2016 |
Last Verified: | June 2016 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Failed IVF cycles IVF outcome parameters endometrial injury |
hysteroscopy pipelle sampling Repeated implantation failures |